NasdaqGS - Nasdaq Real Time Price USD

argenx SE (ARGX)

625.03

-31.62

(-4.81%)

As of 1:07:43 PM EDT. Market Open.

argenx to Present at BofA Securities 2025 Health Care Conference

May 6, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, and members of the management team will present at the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025 at 4:20 p.m. PT. A live webcast of the presentation may be accessed on the Investors section of the argenx website at ar

GlobeNewswire 12 hours ago

ARGNF

ARGX
-4.81%
Is argenx SE (ARGX) the Most Profitable Growth Stock to Buy Now?

We recently published a list of 13 Most Profitable Growth Stocks to Buy Now. In this article, we are going to take a look at where argenx SE (NASDAQ:ARGX) stands against other most profitable growth stocks to buy now. The growth factor in investing refers to companies that grow their revenue and earnings at rates […]

Insider Monkey 5 days ago

ARGX
-4.81%
Exploring High Growth Tech Stocks In Europe

As European markets experience a notable upswing, with the STOXX Europe 600 Index rising by 2.77% amid easing trade tensions and positive economic signals, investors are increasingly focusing on high-growth tech stocks that show resilience and potential in such dynamic conditions. In this environment, a good stock is often characterized by its ability to adapt to market changes and leverage technological advancements to drive growth, making it a key consideration for those exploring...

Simply Wall St. 5 days ago

OTGLF

OTGLY

RMDEF
argenx to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025

May 1, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, May 8, 2025 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its first quarter 2025 financial results and provide a business update. A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.co

GlobeNewswire 5 days ago

ARGNF

ARGX
-4.81%
Argenx Stock Extends Rally In A Base As Earnings Loom

Argenx stock is rising Wednesday as the major indexes sell off. The autoimmune disease treatment stock is climbing in an early-stage base.

Investor's Business Daily 6 days ago

ARGNF

ARGX
-4.81%
argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

VYVGART® is first-and-only targeted IgG Fc-antibody fragment for CIDPFirst novel mechanism of action for CIDP treatment in more than 30 yearsCHMP positive opinion based on ADHERE data, the largest ever CIDP clinical trial European Commission (EC) decision on marketing authorization application (MAA) expected within approximately two months April 28, 2025, 07:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of

GlobeNewswire 8 days ago

ARGNF

ARGX
-4.81%
Argenx (ARGX) Moves 4.4% Higher: Will This Strength Last?

Argenx (ARGX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks 21 days ago

ARGX
-4.81%
Is Argenx SE (ARGX) the Best Growth Stock to Buy According to Billionaires?

We recently published a list of 10 Best Growth Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Argenx SE (NASDAQ:ARGX) stands against other best growth stocks to buy according to billionaires. Can the Stock Market Have a Big Rebound? The stock market has been on […]

Insider Monkey 21 days ago

ARGX
-4.81%
FDA Approves Argenx's Vyvgart Hytrulo Prefilled Syringe For Self-Injection For At Home Use Setting

The U.S. Food and Drug Administration (FDA) on Thursday approved a new option for patients to self-inject Argenx SE’s (NASDAQ:ARGX) Vyvgart Hytrulo with a prefilled syringe (efgartigimod alfa and hyaluronidase-qvfc) for adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive and adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP). Vyvgart Hytrulo prefilled syringe for self-injection is approved as a 20-to-30-se

Benzinga 24 days ago

ARGX
-4.81%
argenx Announces Annual General Meeting of Shareholders on May 27, 2025

April 11, 2025, 10:01 PM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Annual General Meeting of shareholders will be held at 13:00 CET on Tuesday, May 27, 2025 at the Hilton Amsterdam Schiphol at Schiphol Boulevard 701, 1118 BN Schiphol, the Netherlands.The shareholders and all other persons with meeting rights are invited to attend t

GlobeNewswire 24 days ago

ARGNF

ARGX
-4.81%
Argenx Bounds Off 200-Day Line On 'Best-Case Scenario' For Blockbuster Drug

Argenx stock jumped Friday after the FDA cleared its autoimmune disease drug, Vyvgart Hytrulo, for at-home treatment.

Investor's Business Daily 25 days ago

ARGNF

ARGX
-4.81%
argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy

VYVGART, the first-in-class FcRn blocker, now offers three administration options, including self-injection with a prefilled syringeSelf-injection provides gMG and CIDP patients with flexibility for when and where to receive treatment – at home, while ‘on the go’ or in a healthcare setting Approval reflects commitment to innovating the patient experience with individualized, safe and effective therapies April 10, 2025, 11:45 PM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX)

GlobeNewswire 25 days ago

ARGNF

ARGX
-4.81%
argenx SE (ARGX): Among the Aggressive Stocks Picked by Hedge Funds

We recently published a list of Aggressive Stock Portfolio: 12 Stocks Picked by Hedge Funds. In this article, we are going to take a look at where argenx SE (NASDAQ:ARGX) stands against other aggressive stocks picked by hedge funds. The broader market has dropped into correction territory, declining by over 10% from its peak in […]

Insider Monkey 25 days ago

COMP

ARGX
-4.81%
Argenx's Flagship Drug Vyvgart Shows Sustained Disease Control In Rare Neuromuscular Disease Patients

Argenx SE (NASDAQ:ARGX) showcased long-term data of Vyvgart (IV: efgartigimod alfa-fcab and SC or Hytrulo: efgartigimod alfa and hyaluronidase-qvfc) demonstrating sustained disease control of generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP) with a favorable safety profile. ADAPT-NXT Part B data demonstrated clinically meaningful improvements as early as Week 1 with Vyvgart’s bi-weekly and every three-week dosing schedules. Over the course of the st

Benzinga 27 days ago

ARGX
-4.81%
argenx Highlights VYVGART Data at AAN 2025 Setting New Standard in Sustained Efficacy and Improved Quality of Life Measures for Patients Living with gMG and CIDP

ADAPT-NXT data demonstrate consistent, sustained disease control across dosing schedules, further supporting individualized VYVGART dosing for gMG patients ADHERE+ oral presentation features long-term CIDP data demonstrating VYVGART Hytrulo’s durable efficacy, sustained functional improvements and favorable safety profileargenx continues to advance a robust neuromuscular pipeline of clinical candidates; first-in-human data of ARGX-119 (MuSK agonist) support pipeline-in-a-product development plan

GlobeNewswire 28 days ago

ARGNF

ARGX
-4.81%
Is Argenx SE (ARGX) The Most Profitable Biotech Stock To Buy Right Now?

We recently published a list of 7 Most Profitable Biotech Stocks To Buy Right Now. In this article, we are going to take a look at where Argenx SE (NASDAQ:ARGX) stands against other most profitable biotech stocks to buy right now. With improved market conditions, innovative breakthroughs, and more investor interest, the biotechnology industry is […]

Insider Monkey last month

ARGX
-4.81%
Exploring Three High Growth Tech Stocks in Europe

As European markets navigate the challenges of new U.S. trade tariffs and fluctuating economic indicators, the pan-European STOXX Europe 600 Index recently experienced a decline of about 1.4%, reflecting broader market sentiment impacted by geopolitical tensions and inflation concerns. In this environment, identifying high-growth tech stocks requires a focus on companies with strong fundamentals and innovative capabilities that can adapt to shifting market dynamics while maintaining robust...

Simply Wall St. last month

OTGLF

OTGLY

ARGNF
Argenx (ARGX) Surges 4.1%: Is This an Indication of Further Gains?

Argenx (ARGX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks last month

ARGX
-4.81%

STOK
Artisan Small Cap Fund Sold argenx SE (ARGX) as it Exceeded Small-Cap Mandate

Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here. US stocks concluded a strong year with strong gains in Q4. In Q4, the portfolio’s performance was flat and narrowly trailed the Russell 2000® Growth Index. In 2024, the […]

Insider Monkey last month

ARGX
-4.81%

^RUT
argenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the American Academy of Neurology 2025 Annual Meeting

Largest safety data set on FcRn blocking demonstrates consistent, favorable safety profile of VYVGART and VYVGART HytrulogMG patients on VYVGART achieve rapid, substantial, and sustained efficacy across multiple dosing regimens, supporting individualized treatment approachADHERE+ oral presentation builds upon evidence of VYVGART Hytrulo driving improved functional ability in CIDP Amsterdam, the Netherlands – March 7, 2025 – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committ

GlobeNewswire last month

ARGNF

ARGX
-4.81%

Performance Overview

Return	ARGX	BEL 20 (^BFX)
YTD	+0.82%	+5.67%
1-Year	+61.01%	+13.66%
3-Year	+95.12%	+11.05%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

argenx SE (ARGX)

argenx to Present at BofA Securities 2025 Health Care Conference

Is argenx SE (ARGX) the Most Profitable Growth Stock to Buy Now?

Exploring High Growth Tech Stocks In Europe

argenx to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025

Argenx Stock Extends Rally In A Base As Earnings Loom

argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Argenx (ARGX) Moves 4.4% Higher: Will This Strength Last?

Is Argenx SE (ARGX) the Best Growth Stock to Buy According to Billionaires?

FDA Approves Argenx's Vyvgart Hytrulo Prefilled Syringe For Self-Injection For At Home Use Setting

argenx Announces Annual General Meeting of Shareholders on May 27, 2025

Argenx Bounds Off 200-Day Line On 'Best-Case Scenario' For Blockbuster Drug

argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy

argenx SE (ARGX): Among the Aggressive Stocks Picked by Hedge Funds

Argenx's Flagship Drug Vyvgart Shows Sustained Disease Control In Rare Neuromuscular Disease Patients

argenx Highlights VYVGART Data at AAN 2025 Setting New Standard in Sustained Efficacy and Improved Quality of Life Measures for Patients Living with gMG and CIDP

Is Argenx SE (ARGX) The Most Profitable Biotech Stock To Buy Right Now?

Exploring Three High Growth Tech Stocks in Europe

Argenx (ARGX) Surges 4.1%: Is This an Indication of Further Gains?

Artisan Small Cap Fund Sold argenx SE (ARGX) as it Exceeded Small-Cap Mandate

argenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the American Academy of Neurology 2025 Annual Meeting

Performance Overview